ITGAM and neoplasm: FACS data showed that CD11b+Gr-1+MDSCs significantly increased in the spleen of untreated tumor-bearing mice compared with the normal mice (up to 61.3 ± 8.02% vs 1.81 ± 0.19%), while the content of MDSCs in the spleen of tumor bearing mice after GFI treatment decreased to 56.6 ± 6.74% (GFI-LD), 49.1 ± 11.2% (GFI-MD) and 18.2 ± 5.14%, respectively (Fig. 6D).